Form D · Biotechnology
Inflection Point Genetics Inc.
St. Louis, MO · CIK 0001953599
Offering snapshot reported Nov 8, 2022 · SEC filing
- Reported sold
- $265K Offering amount: $1M
- Investors reported
- 6 Form D · investor count
- Minimum accepted
- $15K Reported outside-investor minimum
- First sale
- Oct 24, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Nov 8, 2022 | Initial | $265,005 | No comparison | 6 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-464185
Source: Form D, filed Nov 8, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Edward Weinstein | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
4340 Duncan Avenue Suite 278
St. Louis, MO, 63110
St. Louis, MO, 63110